Credit Suisse’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Credit Suisse’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,300	Closed	-$12K	–	4111
2018 Q2	$12K	Hold	1,300	–	–	﹤0.01%	3936
2018 Q1	$11K	Hold	1,300	–	–	﹤0.01%	3934
2017 Q4	$13K	Hold	1,300	–	–	﹤0.01%	3949
2017 Q3	$20K	Buy	+1,300	New	+$15.3K	﹤0.01%	4157
2013 Q3	–	Sell	-203	Closed	-$95K	–	4433
2013 Q2	$95K	Buy	+203	New	+$92.1K	﹤0.01%	4027

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Credit Suisse's IDXG Position: Q3 2018 in Review

Credit Suisse sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2018, closing a stake of 1,300 shares — an estimated $12K sold.

Credit Suisse first reported a position in IDXG in Q2 2013 and held it in 5 quarters. The position peaked at $95K in Q2 2013. 18 funds tracked by Wall St. Rank hold IDXG as of Q3 2018.

Credit Suisse reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Credit Suisse sold 1,300 Interpace Biosciences, Inc. Common Stock shares in Q3 2018, an estimated $12K.
Credit Suisse first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
Credit Suisse's Interpace Biosciences, Inc. Common Stock position peaked at $95K in Q2 2013.
18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2018.

Based on Credit Suisse's 13F filing for Q3 2018, filed 13 Nov 2018.